mRNA平台市场 - 全球产业规模、份额、趋势、机会及预测（按适应症、易用性、mRNA类型、最终用户、地区和竞争格局划分，2021-2031年）

全球 mRNA 平台市场预计将从 2025 年的 75.2 亿美元成长到 2031 年的 95.9 亿美元，年复合成长率为 4.14%。

此领域涵盖利用传讯RNA指导宿主细胞内特定蛋白质的合成，并透过脂质奈米颗粒等递送系统实现疾病的预防和治疗。推动这一领域发展的关键因素包括感染疾病爆发期间对快速疫苗开发平台的迫切需求，以及将该方法拓展至肿瘤学和罕见疾病治疗领域的大规模投资。 mRNA药物联盟的报告强调了生产的重要性，报告指出，到2025年，49%的受访行业组织认为生产工艺效率是提高全球mRNA药物可负担性和可及性的关键因素。

儘管取得了这些进展，但由于mRNA分子固有的不稳定性，市场仍面临巨大的障碍。这项特性要求严格的超低温储存和运输。这种技术要求导致高昂的基础设施成本和复杂的物流配送，尤其是在资源匮乏的地区。因此，这些物流障碍限制了mRNA产品的顺利商业性化应用，使其主要局限于大型製药市场，阻碍了其在全球范围内的进一步扩张。

市场驱动因素

推动市场成长的关键动力在于策略性地拓展至癌症治疗和罕见遗传疾病领域，这促使该技术超越其在感染疾病预防领域最初的成功。研发人员正在加速开发个人化癌症免疫疗法，利用mRNA的可程式设计训练免疫系统识别新肿瘤特异性抗原，从而有效降低对疫情相关收入的依赖，同时满足复杂的未满足医疗需求。这种向新适应症的转变在行业趋势中得到了清晰的体现。例如，Moderna于2025年1月宣布，其五款针对癌症、罕见疾病和潜在疫苗的非呼吸系统候选药物已进入临床实验试验阶段，这标誌着该公司正全面进军这些新兴治疗领域。

此外，注入公共和私人资本，并辅以策略联盟，对于克服高昂的研发成本和扩大生产能力至关重要。大型製药公司正投入大量资源来加强供应链，并加速下一代产品的研发，通常透过合资和许可的方式来分担风险。例如，赛诺菲在2025年5月宣布，计画在2030年在美国的研发和生产领域投资至少200亿美元。同样，为了体现这些金融联盟的规模，BioNTech在2025年3月宣布，预计在2025和2026财年将从合作伙伴处获得约5.35亿美元的报销。

市场挑战

mRNA分子固有的不稳定性是全球mRNA平台市场发展的一大障碍，因此必须采用严格的超低温炼式储存和运输通讯协定。这项要求迫使生产商依赖专门的、资本密集的基础设施，例如超低温储存单元和温控运输货柜，而这些设施在开发中国家往往供应短缺。因此，建构这些复杂的配送网络的高昂成本极大地限制了mRNA疗法的商业性化应用，使其主要局限于拥有成熟医药物流动能力的富裕地区。

对复杂低温运输系统的依赖阻碍了全球扩张，因为分销中断会带来巨大的财务风险。大量高价值治疗药物在全球价值链中流通，更凸显了这种依赖关係。根据国际航空运输协会（IATA）预测，到2024年，製药业将运输价值1兆美元的货物，凸显了温控生物製药运输的巨大经济效益和基础设施需求。除非这些物流负担得到缓解，否则mRNA疗法在主要经济体以外的地区实现公平取得和顺利商业性成长方面将继续面临挑战。

市场趋势

人工智慧和机器学习在序列优化领域的融合，透过高精度预测翻译效率和免疫抗原性，正在革新mRNA疗法的设计。透过深度学习演算法分析海量mRNA序列资料集，研发人员可以辨识出最佳的密码子使用和结构构型，从而在最大限度地提高蛋白质生产的同时，最大限度地降低不稳定性。这种计算策略加速了候选药物的发现，显着减少了对重复性湿实验的依赖，并加快了从概念到临床试验的转化。例如，在2025年10月的AI Day上，InstaDeep展示了其最新的AI模型在识别新型肽靶点方面，准确率提高了10-15%，推理速度提高了50倍，凸显了计算生物学在提升效率方面的巨大潜力。

同时，环状RNA（circRNA）技术的进步代表着一种结构上的转变，旨在克服线性mRNA分子寿命短的缺陷。透过将RNA工程化为共用闭合的环状结构，这些平台能够抵抗核酸外切酶的降解，并实现更持久的蛋白质表现。这使得药物剂量可以降低，毒性风险也随之降低。这种结构创新在需要持续治疗效果的治疗领域中尤其重要，例如蛋白质替代疗法，将市场拓展到急性疫苗应用之外。 2025年12月，Ohna Therapeutics公司公布了临床前数据，显示其领先的环状RNA候选药物在非人灵长类动物中仅以0.1 mg/kg的剂量即可实现强效的免疫细胞清除效果，证明了该平台具有增强疗效和延长作用持续时间的潜力。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球mRNA平台市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依适应症（自体免疫疾病、癌症、感染疾病、罕见疾病、呼吸系统疾病）
  • 依用途（预防性疫苗、治疗性疫苗、治疗性疫苗）
  • 依mRNA类型（核苷修饰的mRNA、自扩增mRNA、未修饰的mRNA）
  • 依最终用户（医院/诊所、製药公司、研究机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美mRNA平台市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲mRNA平台市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章 亚太地区mRNA平台市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲mRNA平台市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章 南美mRNA平台市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球mRNA平台市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global mRNA Platform Market is projected to expand from USD 7.52 Billion in 2025 to USD 9.59 Billion by 2031, reflecting a compound annual growth rate of 4.14%. This sector encompasses technologies that employ messenger RNA to guide host cells in synthesizing specific proteins, enabling disease prevention and treatment through delivery systems like lipid nanoparticles. Key catalysts fueling this growth include the critical need for rapid vaccine development platforms during infectious outbreaks and the massive investment directed toward extending this modality into oncology and rare disease treatments. Highlighting the focus on production, the Alliance for mRNA Medicines reported in 2025 that 49% of surveyed industry organizations pinpointed manufacturing processing efficiency as a primary element for enhancing the global affordability and accessibility of mRNA-based medicines.

Despite these advancements, the market faces a substantial hurdle due to the inherent instability of mRNA molecules, which mandates rigorous ultra-cold chain logistics for both storage and transport. This technical requirement results in elevated infrastructure expenses and complicated distribution logistics, particularly in resource-constrained areas. Consequently, these logistical barriers restrict the seamless commercial adoption of mRNA products, largely confining their availability to major pharmaceutical markets and impeding broader global expansion.

Market Driver

A pivotal growth engine for the market is the strategic expansion into oncology and rare genetic disorders, propelling the technology beyond its initial triumphs in infectious disease prevention. Developers are increasingly utilizing the programmability of mRNA to engineer personalized cancer immunotherapies that train the immune system to detect tumor-specific neoantigens, effectively reducing dependence on pandemic-related revenue while addressing complex, unmet medical needs. This shift toward new indications is evident in industry activities; for instance, Moderna reported in January 2025 that it had advanced five non-respiratory candidates into pivotal studies covering cancer, rare diseases, and latent vaccines, signaling a robust pivot toward these emerging therapeutic areas.

Additionally, the infusion of public and private capital, bolstered by strategic alliances, is crucial for surmounting steep development costs and scaling manufacturing capacities. Leading pharmaceutical companies are dedicating massive resources to fortify supply chains and expedite R&D for next-generation assets, often utilizing joint ventures and licensing deals to share risk. To illustrate this commitment, Sanofi announced in May 2025 a plan to invest at least $20 billion in U.S.-based research, development, and manufacturing through 2030. Similarly, highlighting the magnitude of these financial partnerships, BioNTech projected in March 2025 that it would receive approximately $535 million in reimbursements from its collaboration partner over the 2025 and 2026 fiscal years.

Market Challenge

The fundamental instability of the mRNA molecule acts as a formidable obstacle to the Global mRNA Platform Market, necessitating strict ultra-cold chain protocols for storage and transportation. This requirement compels manufacturers to depend on specialized, capital-intensive infrastructure, such as deep-freeze storage units and temperature-controlled shipping containers, which are frequently scarce in developing nations. As a result, the exorbitant costs involved in building these intricate distribution networks severely restrict the commercial scope of mRNA therapeutics, effectively limiting their primary adoption to affluent regions that possess established pharmaceutical logistics capabilities.

Reliance on such sophisticated cold chain systems hinders global expansion, as the financial risks linked to distribution failures are prohibitive. The scale of this dependency is underscored by the immense volume of high-value treatments traversing the global supply chain; according to the International Air Transport Association (IATA), the pharmaceutical industry transported over US$ 1 trillion worth of cargo in 2024, emphasizing the massive economic stakes and infrastructure requirements for shipping temperature-sensitive biologics. Unless these logistical burdens are alleviated, the mRNA modality will continue to struggle with achieving equitable accessibility and seamless commercial growth outside of major economic centers.

Market Trends

The integration of AI and Machine Learning for sequence optimization is transforming the design of mRNA therapeutics by predicting translation efficiency and immunogenicity with high precision. By employing deep learning algorithms to examine extensive datasets of mRNA sequences, developers can identify optimal codon usage and structural configurations that maximize protein output while minimizing instability. This computational strategy accelerates candidate discovery, significantly lowering the dependence on iterative wet-lab experimentation and speeding up the move from concept to clinical trials. For example, during its 'AI Day' in October 2025, InstaDeep demonstrated that its newest AI model offered a 10-15% improvement in accuracy and 50-fold faster inference speeds for identifying novel peptide targets, highlighting the efficiency gains provided by computational biology.

Concurrently, the advancement of Circular RNA (circRNA) technologies marks a structural shift designed to overcome the transient nature of linear mRNA molecules. By engineering RNA into a covalently closed loop, these platforms resist degradation by exonucleases, enabling more durable protein expression and permitting lower dosing regimens that decrease toxicity risks. This architectural innovation is especially critical for therapeutic areas requiring sustained treatment effects, such as protein replacement therapies, pushing the market beyond acute vaccine applications. In December 2025, Orna Therapeutics presented preclinical data indicating that its lead circular RNA candidate achieved robust immune cell depletion in non-human primates at doses as low as 0.1 mg/kg, validating the platform's potential for enhanced potency and extended duration.

Key Market Players

• AstraZeneca PLC
• Asuragen, Inc.
• Catalent Pharma Solutions
• Arcturus Therapeutics, Inc.
• BioNTech AG
• CRISPR Therapeutics Inc.
• AKESOgen, Inc.
• baseclick GmbH
• Accent Therapeutics Inc.
• Accanis Biotech F&E GmbH & Co KG

Report Scope

In this report, the Global mRNA Platform Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Platform Market, By Indication

• Autoimmune Diseases
• Cancer
• Infectious Diseases
• Rare Diseases
• Respiratory Diseases

mRNA Platform Market, By Usability

• Prophylactic Vaccines
• Therapeutic Drugs
• Therapeutic Vaccines

mRNA Platform Market, By mRNA Type

• Nucleoside-Modified mRNA
• Self-Amplifying mRNA
• Unmodified mRNA

mRNA Platform Market, By End User

• Hospitals & Clinics
• Pharmaceutical Companies
• Research Organization

mRNA Platform Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global mRNA Platform Market.

Available Customizations:

Global mRNA Platform Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global mRNA Platform Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Autoimmune Diseases, Cancer, Infectious Diseases, Rare Diseases, Respiratory Diseases)
  • 5.2.2. By Usability (Prophylactic Vaccines, Therapeutic Drugs, Therapeutic Vaccines)
  • 5.2.3. By mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA)
  • 5.2.4. By End User (Hospitals & Clinics, Pharmaceutical Companies, Research Organization)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America mRNA Platform Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Usability
  • 6.2.3. By mRNA Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States mRNA Platform Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Usability
      • 6.3.1.2.3. By mRNA Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada mRNA Platform Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Usability
      • 6.3.2.2.3. By mRNA Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico mRNA Platform Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Usability
      • 6.3.3.2.3. By mRNA Type
      • 6.3.3.2.4. By End User

7. Europe mRNA Platform Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Usability
  • 7.2.3. By mRNA Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany mRNA Platform Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Usability
      • 7.3.1.2.3. By mRNA Type
      • 7.3.1.2.4. By End User
  • 7.3.2. France mRNA Platform Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Usability
      • 7.3.2.2.3. By mRNA Type
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom mRNA Platform Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Usability
      • 7.3.3.2.3. By mRNA Type
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy mRNA Platform Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Usability
      • 7.3.4.2.3. By mRNA Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain mRNA Platform Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Usability
      • 7.3.5.2.3. By mRNA Type
      • 7.3.5.2.4. By End User

8. Asia Pacific mRNA Platform Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Usability
  • 8.2.3. By mRNA Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China mRNA Platform Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Usability
      • 8.3.1.2.3. By mRNA Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India mRNA Platform Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Usability
      • 8.3.2.2.3. By mRNA Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan mRNA Platform Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Usability
      • 8.3.3.2.3. By mRNA Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea mRNA Platform Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Usability
      • 8.3.4.2.3. By mRNA Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia mRNA Platform Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Usability
      • 8.3.5.2.3. By mRNA Type
      • 8.3.5.2.4. By End User

9. Middle East & Africa mRNA Platform Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Usability
  • 9.2.3. By mRNA Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia mRNA Platform Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Usability
      • 9.3.1.2.3. By mRNA Type
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE mRNA Platform Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Usability
      • 9.3.2.2.3. By mRNA Type
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa mRNA Platform Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Usability
      • 9.3.3.2.3. By mRNA Type
      • 9.3.3.2.4. By End User

10. South America mRNA Platform Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Usability
  • 10.2.3. By mRNA Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil mRNA Platform Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Usability
      • 10.3.1.2.3. By mRNA Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia mRNA Platform Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Usability
      • 10.3.2.2.3. By mRNA Type
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina mRNA Platform Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Usability
      • 10.3.3.2.3. By mRNA Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global mRNA Platform Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Asuragen, Inc.
• 15.3. Catalent Pharma Solutions
• 15.4. Arcturus Therapeutics, Inc.
• 15.5. BioNTech AG
• 15.6. CRISPR Therapeutics Inc.
• 15.7. AKESOgen, Inc.
• 15.8. baseclick GmbH
• 15.9. Accent Therapeutics Inc.
• 15.10. Accanis Biotech F&E GmbH & Co KG

16. Strategic Recommendations

17. About Us & Disclaimer